• Structure touts 16% weight loss for aleniglipron as 'highest efficacy' for an oral GLP-1 yet
• R1 zooms out of stealth with $77.5M series A to advance chronic kidney disease treatment
• Danish biotech Gubra plots Roivant-like model to churn out new companies

• Stop asking for an AI strategy: 3 questions clinical leaders should ask instead
• The Real Test for AI Diagnostics Isn’t Performance — It’s Clinical Adoption
• Real-World Evidence Meets Machine Learning: What It Takes to Future-Proof Evidence Generation
  

• CytomX surges on positive data for ‘masked’ ADC in colorectal cancer
• Astellas walks away from $1.6B biobucks T-cell engager pact with CytomX after 6 years
• JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity — NeuroSense Therapeutics

Startup Waiv Spins Out of Owkin With $33M to Bring AI Precision to Cancer Decisions

Artificial Intelligence and the Data Quality Problem No One Can Ignore

Microsoft Enters Healthcare Chatbot Race with Copilot Health

• GSK’s RSV vaccine wins broader FDA clearance
• Bimzelx tops Skyrizi in head-to-head psoriatic arthritis trial
• With FDA go ahead, a China biotech notches a first in cell therapy testing

• An AI Driven Approach to Address the Non-Responder Gap in Radiopharmaceutical Therapy
• Agentic AI Swarms Degrade Decision-Making
• STAT+: AI agents are rapidly spreading in health care, but validation is lacking

• Ultragenyx gene therapy hits co-primary endpoint in phase 3 rare disease study, teeing up potential win
• BridgeBio's muscle weakness data impress ahead of FDA filing
• Fledgling French biotech pens $128M deal for Kezar's preclinical protein degrader program

• STAT+: New nonprofit launches with at least $500 million to modernize scientific process for AI era
• Bota/Enhe’s SAION AI push toward closed‑loop, machine‑protocol‑driven biomanufacturing
• Tailored Training Can Address Biopharma Skills Shortage

• Regeneron's obesity drug shows Zepbound-like efficacy in phase 3
• Tenacia builds $308M biobucks deal with Rapport to develop epilepsy drug in greater China
• $270M RNA Drug Spinout Targets Rare Genetic Cardiomyopathies

• Smarter Filings, Smarter Factories
• Health AI startup to benefit from $1 billion funding round for Yann LeCun’s AMI
• Breakout Ventures launches $114M AI-focused fund